AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.an2therapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2026 | $9.00 | Market Perform → Outperform | Leerink Partners |
| 8/9/2024 | In-line → Underperform | Evercore ISI | |
| 8/9/2024 | $5.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 7/3/2024 | $5.00 | Market Perform → Outperform | Leerink Partners |
| 4/2/2024 | $6.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/13/2024 | $23.00 → $7.00 | Outperform → Market Perform | Leerink Partners |
| 2/12/2024 | $25.00 → $7.00 | Outperform → In-line | Evercore ISI |
| 2/12/2024 | Outperform → Perform | Oppenheimer | |
| 2/12/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 1/4/2024 | $30.00 | Mkt Outperform | JMP Securities |
SCHEDULE 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
DEF 14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
DEFA14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
EFFECT - AN2 Therapeutics, Inc. (0001880438) (Filer)
424B3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
424B5 - AN2 Therapeutics, Inc. (0001880438) (Filer)
S-3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $9.00
Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously
Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00
JMP Securities upgraded AN2 Therapeutics from Mkt Perform to Mkt Outperform and set a new price target of $6.00
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $7.00 from $23.00 previously
Evercore ISI downgraded AN2 Therapeutics from Outperform to In-line and set a new price target of $7.00 from $25.00 previously
Oppenheimer downgraded AN2 Therapeutics from Outperform to Perform
JMP Securities downgraded AN2 Therapeutics from Mkt Outperform to Mkt Perform
JMP Securities initiated coverage of AN2 Therapeutics with a rating of Mkt Outperform and set a new price target of $30.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
Fastest customizable press release news feed in the world
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of ch
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the
Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study Declared ENPP1 candidate for solid tumors advancing from early research into development AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in th
Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 20
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc
Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer characterized by overproduction of red blood cells in the bone
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics de
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop, trial will focus on early-stage, treatment-naive patients, a key difference from AN2's previous studies in mycobacterium avium complex (MAC) Patient enrollment expected to be initiated in 1Q 2026 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration has cleared Oregon Health & Science University's (OHSU) Investigational New Drug (IND) application to proceed
Live Leadership Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the
AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a
Live finance-specific insights
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer 2024 Cash and investments of $150.2 million at September 30, 2023; cash runway anticipated to fund operations through summer 2025 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023. "We are incredibly proud of the significant milestones achieved recently and over the p
Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. "We're pleased with the accelerated pace of enrollment in our pivotal Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease and be
Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023. "In the first quarter we continued to advance our pivotal Phase 2/3 trial evaluating epetraborole for treatment-refractory MAC lung disease with a total of nearly 80 clinical sites active worldwide. We are pleased with the momentum we're seeing in the Asia-Pacific region, particularly at
Approaching 60 clinical sites participating in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease to date Opened up sites in three additional countries -- Japan, South Korea, and Australia in addition to the U.S.; Japan has some of the highest rates of MAC lung disease in the world Activities underway to advance development of epetraborole for acute systemic melioidosis using non-dilutive funding AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fou
Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD) Multiple Phase 2a proof-of-concept (POC) clinical data readouts and Phase 2b clinical trial initiations expected in 2023 Operations well-funded through 2025 Company to host conference call today at 8:00 PM HKT / 8:00 AM ET DURHAM, N.C. and BEIJING, March 24, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across disease
This live feed shows all institutional transactions in real time.
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)